| T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial DW Lee, JN Kochenderfer, M Stetler-Stevenson, YK Cui, C Delbrook, ... The Lancet 385 (9967), 517-528, 2015 | 3301 | 2015 |
| Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric … JN Kochenderfer, ME Dudley, SH Kassim, RPT Somerville, RO Carpenter, ... Journal of clinical oncology 33 (6), 540-549, 2015 | 1980 | 2015 |
| B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells JN Kochenderfer, ME Dudley, SA Feldman, WH Wilson, DE Spaner, ... Blood, The Journal of the American Society of Hematology 119 (12), 2709-2720, 2012 | 1850 | 2012 |
| Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 JN Kochenderfer, WH Wilson, JE Janik, ME Dudley, M Stetler-Stevenson, ... Blood, The Journal of the American Society of Hematology 116 (20), 4099-4102, 2010 | 1681 | 2010 |
| Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma N Raje, J Berdeja, YI Lin, D Siegel, S Jagannath, D Madduri, M Liedtke, ... New England Journal of Medicine 380 (18), 1726-1737, 2019 | 1601 | 2019 |
| Toxicities of chimeric antigen receptor T cells: recognition and management JN Brudno, JN Kochenderfer Blood, The Journal of the American Society of Hematology 127 (26), 3321-3330, 2016 | 1425 | 2016 |
| T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma SA Ali, V Shi, I Maric, M Wang, DF Stroncek, JJ Rose, JN Brudno, ... Blood, The Journal of the American Society of Hematology 128 (13), 1688-1700, 2016 | 848 | 2016 |
| Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management JN Brudno, JN Kochenderfer Blood reviews 34, 45-55, 2019 | 837 | 2019 |
| T cells genetically modified to express an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma JN Brudno, I Maric, SD Hartman, JJ Rose, M Wang, N Lam, ... Journal of Clinical Oncology 36 (22), 2267-2280, 2018 | 783 | 2018 |
| B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma RO Carpenter, MO Evbuomwan, S Pittaluga, JJ Rose, M Raffeld, S Yang, ... Clinical cancer research 19 (8), 2048-2060, 2013 | 762 | 2013 |
| Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation JN Kochenderfer, ME Dudley, RO Carpenter, SH Kassim, JJ Rose, ... Blood, The Journal of the American Society of Hematology 122 (25), 4129-4139, 2013 | 727 | 2013 |
| Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell … JN Brudno, RPT Somerville, V Shi, JJ Rose, DC Halverson, DH Fowler, ... Journal of clinical oncology 34 (10), 1112-1121, 2016 | 680 | 2016 |
| Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors JN Kochenderfer, SA Rosenberg Nature reviews Clinical oncology 10 (5), 267-276, 2013 | 600 | 2013 |
| Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels JN Kochenderfer, RPT Somerville, T Lu, V Shi, A Bot, J Rossi, A Xue, ... Journal of clinical oncology 35 (16), 1803-1813, 2017 | 591 | 2017 |
| Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor JN Kochenderfer, SA Feldman, Y Zhao, H Xu, MA Black, RA Morgan, ... Journal of immunotherapy 32 (7), 689-702, 2009 | 571 | 2009 |
| Chimeric antigen receptor T-cell therapies for lymphoma JN Brudno, JN Kochenderfer Nature reviews Clinical oncology 15 (1), 31-46, 2018 | 519 | 2018 |
| Long-term outcomes following CAR T cell therapy: what we know so far KM Cappell, JN Kochenderfer Nature reviews Clinical oncology 20 (6), 359-371, 2023 | 512 | 2023 |
| Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells JN Kochenderfer, Z Yu, D Frasheri, NP Restifo, SA Rosenberg Blood, The Journal of the American Society of Hematology 116 (19), 3875-3886, 2010 | 454 | 2010 |
| A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity Y Zhao, QJ Wang, S Yang, JN Kochenderfer, Z Zheng, X Zhong, ... The Journal of Immunology 183 (9), 5563-5574, 2009 | 437 | 2009 |
| Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies M Sabatino, J Hu, M Sommariva, S Gautam, V Fellowes, JD Hocker, ... Blood, The Journal of the American Society of Hematology 128 (4), 519-528, 2016 | 391 | 2016 |
